🔬 Radiolabeled nanobodies are emerging as powerful tools for cancer immunotherapy, enabling non-invasive imaging of tumours, immune checkpoints, and immune cells to support patient selection and treatment monitoring. 📖 vist.ly/5c72w

🧬 CAR-T cells and TCR-T cells don't regulate cytokine production in the same way. Patel and colleagues show that while co-stimulatory receptors are needed to sustain late cytokine production in TCR-T cells, this regulation is largely lost in 2nd-generation CAR-T cells. 📖 vist.ly/5c3w8

🎗️ Cancer stem cells may be a key missing piece in understanding immunotherapy resistance. This comprehensive review examines how CSCs interact with the tumour microenvironment and discusses emerging strategies to target stemness-driven therapeutic failure. 📖 vist.ly/5btf3

🚀 New in Immunotherapy Advances! Margherita Boieri et al. from Zelluna ASA report promising preclinical data on MAGE‑A4–specific TCR‑NK cells, showing potent, safe activity against solid tumors. Read the open access article: vist.ly/5bip5 #Immunotherapy #CellTherapy

Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders. Read here📄vist.ly/5ba67

NLRC5 is more than an MHC-I regulator. Shukla et al. show that tumour-intrinsic NLRC5 promotes CD8⁺ T-cell and NK-cell infiltration, rewires antigen-processing pathways, and drives tumour control, highlighting its potential as a target to enhance antitumour immunity. 🧬 vist.ly/5b6jx

Tumour‑reactive plasma cells are emerging as powerful players in cancer immunotherapy. This review highlights their role, the promise of neoantigen‑reactive PCs, and the challenges in epitope prediction and screening. 📄 vist.ly/5asfu

A phase 3 study by Kanegane et al. reports that 20% subcutaneous immunoglobulin (Ig20Gly) given weekly or every 2 weeks maintained stable IgG levels with a favourable safety profile in Japanese patients with PIDs. Read the open access article: vist.ly/5adn2

Metabolic dysregulation plays a key role in Behçet’s disease. Elevated glucose & TAG levels drive Th1 differentiation, CD8⁺ T cell activation and B cell antibody production, contributing to immune dysfunction. Read the study: vist.ly/59xtz

CD137 aptamer–shRNA chimeras show promise for targeting intratumoral Tregs. This approach downregulates key genes like EzH2 & Nrp1 in CD137⁺ Tregs and malignant cells, offering a potential new route for tumour immunotherapy. 🔗 vist.ly/59urf

A new study protocol describes a controlled human lung immune challenge using inhaled Resiquimod (R848) to investigate antiviral immune responses and airway inflammation, helping to advance respiratory research and novel therapy development. 🔗 vist.ly/59qts

📍 We're at #OCION2026 today in Oxford! Stop by the Immunotherapy Advances booth to meet our Journals Manager, Laura Franklin, and chat about publishing your latest immunology and immuno-oncology research. We're actively welcoming submissions! 🧬✨

🔬 Monocytes play a key role in MS, balancing inflammation and tissue repair. Shifting from pro-inflammatory to repair-associated subsets could offer new therapeutic approaches. 📖 vist.ly/587dc #Immunology #MultipleSclerosis

🔬 Regulatory B cells are key to immune balance, but their role in autoimmune disease is highly variable. This highlights the need for more personalised approaches to treatment. 📖 vist.ly/56c84

Population modelling reveals key drivers of CAR T-cell dynamics in lymphoma patients, highlighting roles for lymphodepletion, tumour burden, and cytokines like IL-15/IL-7 🧬 🔗 vist.ly/555yn #Immunotherapy #CARTcells #CancerResearch

A high-affinity ImmTAC® bispecific efficiently redirects T cells to target PRAME+ tumour cells, even at very low antigen levels, highlighting its promise across multiple cancers 🧬 🔗 vist.ly/5422m #Immunotherapy #CancerResearch #Tcells #OpenAccess

A simple whole-blood assay enables rapid, in vivo monitoring of engineered TCR T cell function, capturing cytokine responses post-transfer without complex processing. A practical step for tracking cell therapy performance. 🧬 vist.ly/54bta #Immunotherapy #Tcells #CellTherapy

Attending the #CIMT2026 Annual Meeting? Visit Booth 9 to meet Laura Franklin and Abbie Joyce and learn more about publishing cancer immunotherapy research in Immunotherapy Advances. Learn more: vist.ly/53znk

Attending #CIMT2026? Immunotherapy Advances is welcoming submissions to its Cancer Vaccines – Global Advances collection (deadline extended to July 2026). Hear more from Guest Editor Prof Lennard Lee, speaking at CIMT today at 14:00. #CancerVaccines #Immunotherapy

📢 New open‑access pediatric PID study published: fSCIG 10% maintains stable IgG levels in children aged 2–<16 years, with consistent pharmacokinetics across age groups and support for every‑3–4‑week dosing, helping reduce treatment burden without compromising efficacy. 🔗 vist.ly/53cur

Marking World Immunization Week 2026 with a call for papers for Cancer Vaccines: Global Advances, highlighting cutting‑edge research in personalised and off‑the‑shelf cancer vaccines. Submissions open until April 2026. 🧬 #WorldImmunizationWeek #CancerVaccines #CallForPapers

📢 Last chance to submit! Cancer Vaccines – Global Advances We invite research, reviews, clinical studies, commentaries & TrialsWatch articles on personalised and off‑the‑shelf cancer vaccines. Submit by the end of April 2026 #callforpapers

📢 Call for submissions: CD40 turns 40 – Four Decades of “Forty”‑fying Immunotherapy We welcome research on CD40/CD154 biology and therapeutic targeting in cancer, autoimmunity, transplantation, allergy & more. ⏰ Submit by June 2026: vist.ly/4zcxi

New open‑access paper outlines how the UK Vaccine Innovation Pathway is accelerating cancer vaccine trials across the NHS, boosting recruitment, streamlining delivery, and supporting equitable access. vist.ly/4x25i

New research shows that adding CD28 signalling motifs to the CD3ζ chain boosts IL‑2 production and expansion of TCR‑engineered T cells, without reducing cytotoxicity. A promising step toward stronger TCR therapies for solid tumours. Read here: vist.ly/4wxea #Immunotherapy #TCells

New study shows the Systemic Immune‑Inflammation Index (SIII) is linked to survival in patients on immune checkpoint inhibitors, with lower SIII predicting better outcomes. Read here: vist.ly/4wedi #Immunotherapy #CancerResearch

New study maps the spatial + immune landscape of metastatic dMMR colorectal cancer, revealing why some lesions respond to immunotherapy while others resist. Macrophage polarization and spatial immune architecture emerge as key drivers of outcome. 🔗 vist.ly/4v6u2

📣 Call for Papers! CD40 turns 40: Four Decades of “Forty”-fying Immunotherapy — is open for submissions until March 2026. Share your work on CD40/CD154 biology, therapeutic targeting, and future immunotherapy innovations. Learn more about submitting here: vist.ly/4us3h

New review by Bouvain et al. highlights how ¹⁹F MRI is transforming immune imaging, offering precise inflammation detection and theranostic potential. Exciting advances include targeted neutrophil manipulation in colitis with improved outcomes. 🔗 vist.ly/4unwr

🔬 New open‑access research shows how T‑cell signals (CD40L & IL‑4) can reduce NK‑cell ADCC against malignant B cells, revealing a resistance mechanism to anti‑CD20 therapy. Combining anti‑CD20 + anti‑NKG2A may overcome it. Read: vist.ly/4tzga